RxDoctor Payments Data

Thaihang Nguyen, DO

Family Medicine · Douglas, GANPI 1053635078

Payments from drug & device makers

$14,883in general payments, 2019–2025

Across 918 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$1K
  • Lilly USA, LLC$753
  • Boehringer Ingelheim$745
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$14,78399%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,883 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$206,243
Medicare patients
329
Services billed
3,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide534$617,958
EliquisApixaban302$260,232
FarxigaDapagliflozin Propanediol209$208,352
OzempicSemaglutide169$199,476
JardianceEmpagliflozin163$166,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter150$147,007
LinzessLinaclotide115$95,370
Tresiba Flextouch U-100Insulin Degludec60$67,720
Tresiba Flextouch U-200Insulin Degludec62$67,545
JanuviaSitagliptin Phosphate54$65,988
XareltoRivaroxaban54$56,192
MyrbetriqMirabegron81$53,045
EntrestoSacubitril/Valsartan62$51,871
Repatha SureclickEvolocumab74$50,805
VraylarCariprazine Hcl22$44,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$753$655,254565 claims
PfizerEliquis$691$260,232302 claims
Novo NordiskOzempic, Rybelsus$2,142$230,585196 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Glyxambi$745$219,410237 claims
AstraZenecaFarxiga$1,974$208,352209 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,146$195,085233 claims
AbbVieLinzess, Vraylar, Ubrelvy, Synthroid$1,511$161,356216 claims
MerckJanuvia, Janumet$455$81,43269 claims
Johnson & JohnsonXarelto$257$56,19254 claims
Astellas Pharma US IncMyrbetriq$373$53,04581 claims
NovartisEntresto$220$51,87162 claims
BayerKerendia$470$8,43111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Douglas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →